Portable Imaging Device Assesses Tissue Oxygenation

The images and data can thus provide hyperspectral tissue oxygenation measurements for the selected tissue regions in patients with compromised vascular systems, such as those who suffer from diabetes, peripheral vascular disease (PAD), and limb ischemia.

The patented technology uses proprietary hyperspectral imaging technology to differentiate light absorption patterns between oxygenated hemoglobin and deoxygenated hemoglobin. Software tools then allow the clinician to analyze various areas within the image corresponding to locations on the skin surface, thus determining the location of ischemic tissue. The HyperView is a product of HyperMed Imaging, and has been approved by the U.S. Food and Drug Administration (FDA).

“The new HyperView product represents a significant advancement in non-invasive assessment of superficial tissue oxygenation. We began years ago by first meeting with clinicians to understand their working environment and determine user requirements,” said Mark Darty, President and CEO of HyperMed. “The need for portability, ease of use, and speed of imaging required a full custom design for the HyperView product. Our team’s effort has long been energized by a belief that the HyperView product holds great potential to positively impact the lives of millions of patients.”

“The HyperView is a new and innovative product that can provide clinicians a better understanding of surface perfusion and localized oxygen delivery in patients with potential circulatory compromise, which is important for a number of applications including limb ischemia, wound healing, and reconstructive surgery,” said Professor Aristidis Veves, MD, of Harvard Medical School (Boston, MA, USA), chairman of HyperMed Imaging’s scientific advisory board.